Carol Pilbeam

Bone Research/Osteoporosis, University of Connecticut Health Center, United States of America

Carol C. Pilbeam

Academic positions:
- Professor of Medicine

All industry positions (in last five years):
None declared

Research interests:
Prevention of osteoporosis; role of cyclooxygenase-2 (COX-2) and prostaglandins in bone resorption and formation; effects of mechanical loading on bone; molecular regulation of COX-2 transcription and mRNA stability; role of COX-2 in cell proliferation and apoptosis.

Any other information:
Associate Editor, Prostaglandins and Other Lipids (2003-present)
Ad hoc member of various NIH study sections, including Orthopedics, P30 Core Center for Musculoskeletal Disorders, and R03 programs; member of Women in Bone and Mineral Research committee to enhance professional development of women, ASBMR, 2005-2008.

Associations: Sigma Xi, The Endocrine Society, American Society for Bone and Mineral Research

Donaghue Investigator Award, 2002-2007

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Rheumatology & Clinical Immunology > Bone Biology, Osteoporosis & Other Diseases of Bone (since 15 November 2005)

Links

http://grad.uchc.edu/phdfaculty/pilbeam.html

All recent recommendations

• 3.0
  The risk of fracture following hospitalization in older women and men.
  Recommended by Carol Pilbeam with Katherine Blackwell
  
• 3.0
  Enzyme replacement therapy for murine hypophosphatasia.
  Recommended by Carol Pilbeam with Katherine Blackwell
  
• 6.8
  Endocrine regulation of energy metabolism by the skeleton.
  Recommended by Carol Pilbeam, Chantal Chenu, Gunter Stalla, Tsutomu Takeuchi
  
• 3.0
  Lifelong accumulation of bone in mice lacking Pten in osteoblasts.
  Recommended by Carol Pilbeam
  
• 3.0
  The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
  Recommended by Carol Pilbeam
  
• 6.4
  FSH directly regulates bone mass.
  Recommended by Lee Weinstein, Carol Pilbeam
  
• 3.0
  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
  Recommended by Carol Pilbeam